Literature DB >> 21748108

Antiphosphatidyl serine autoantibodies and premature coronary events.

Hisham Y M Ali1, Zainalabideen A Abdullah.   

Abstract

OBJECTIVES: To determine whether antiphosphatidyl serine autoantibodies (aPS) are associated with increased risk of occurrence of coronary events in selected patients.
METHODS: This study compared 50 patients with coronary events with 30 controls, recruited from the cities of Mosul, Erbil, and Dohuk cities, Northern Iraq, between March 2004 and March 2005. The patient group consisted of 23 individuals with myocardial infarction and 27 with angina. We evaluated the presence of aPS antibodies (IgG and IgM isotypes) by an enzyme-linked immunosorbent assay. The studied cases were less than 50 years of age (mean ± SD, 39.6 ± 5.9) and had no recognizable risk factors.
RESULTS: The frequency of detecting IgG aPS was 10/50 (20%) among patients and 1/30 (3.3%) among controls, with significant difference and with adjusted odds ratio (OR) of 3.2 (95%CI, 1.1-9.1; p < 0.05). The IgM aPS frequency was 3/50 (6%) among patients and zero in the controls, with non-significant difference. The three cases were also IgG positive (i.e. the frequency rate for detection of aPS of IgM was the same as for IgG). Moreover, this marker (aPS) was detected in 8/12 (66.7%) of cases with unstable angina, in 2/15 (13.3%) with stable angina, and in none of the cases with myocardial infarction.
CONCLUSION: IgG aPS autoantibodies are associated with increased risk of coronary events especially angina of unstable subset.

Entities:  

Keywords:  Antiphosphatidyl Serine; Autoantibodies; Events; coronary

Year:  2007        PMID: 21748108      PMCID: PMC3074886     

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  25 in total

1.  Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor.

Authors:  I Salemink; R Blezer; G M Willems; M Galli; E Bevers; T Lindhout
Journal:  Thromb Haemost       Date:  2000-10       Impact factor: 5.249

2.  High prevalence of anti-beta2 glycoprotein I antibodies in patients with ischemic heart disease.

Authors:  A Farsi; M P Domeneghetti; S Fedi; M Capanni; B Giusti; R Marcucci; L Giurlani; D Prisco; A Passaleva; G F Gensini; R Abbate
Journal:  Autoimmunity       Date:  1999       Impact factor: 2.815

3.  Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Thrombogenic Factors, and Recurrent Coronary Events Investigators.

Authors:  A Bili; A J Moss; C W Francis; W Zareba; L F Watelet; I Sanz
Journal:  Circulation       Date:  2000-09-12       Impact factor: 29.690

4.  beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program.

Authors:  R L Brey; R D Abbott; J D Curb; D S Sharp; G W Ross; C L Stallworth; S J Kittner
Journal:  Stroke       Date:  2001-08       Impact factor: 7.914

5.  Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids.

Authors:  J Rauch; M Tannenbaum; A S Janoff
Journal:  Thromb Haemost       Date:  1989-11-24       Impact factor: 5.249

6.  Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men.

Authors:  O Vaarala; M Mänttäri; V Manninen; L Tenkanen; M Puurunen; K Aho; T Palosuo
Journal:  Circulation       Date:  1995-01-01       Impact factor: 29.690

Review 7.  Antiphospholipid antibody syndrome: new insights on thrombogenic mechanisms.

Authors:  J H Rand
Journal:  Am J Med Sci       Date:  1998-08       Impact factor: 2.378

8.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

Authors:  H P McNeil; R J Simpson; C N Chesterman; S A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

9.  Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group.

Authors: 
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

10.  Influence of anticardiolipin antibodies on immediate patient outcome after myocardial infarction.

Authors:  C Raghavan; J Ditchfield; R J Taylor; M R Haeney; P C Barnes
Journal:  J Clin Pathol       Date:  1993-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.